Contract manufacturing organization

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

Retrieved on: 
Wednesday, January 17, 2024
Doctor of Philosophy, SAN, Woman, Contract manufacturing organization, CMOS, CMO, Bill, Pharmaceutical industry

SAN DIEGO, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it has received a grant from the Bill & Melinda Gates Foundation (the foundation) of $750,000 to fund activities related to bacteria-based live biotherapeutic product development.

Key Points: 
  • SAN DIEGO, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it has received a grant from the Bill & Melinda Gates Foundation (the foundation) of $750,000 to fund activities related to bacteria-based live biotherapeutic product development.
  • Daré previously received a grant of approximately $585,000 from the foundation for development of a hydrogel formulation for delivery of live biotherapeutics to support vaginal health in November 2022.
  • The additional grant is intended to cover the costs of Daré personnel to gather and analyze data on the global bacterial biologic supply chain to help the foundation identify potential Contract Manufacturing Organization (CMO) partners for manufacturing clinical and commercial supplies of bacteria-based biotherapeutic products.
  • This work will benefit women and newborns as the primary patient populations for interventions where bacteria consortia products are an important modality in the therapeutic arsenal,” said David Friend, PhD, Chief Scientific Officer of Daré Bioscience.

e2e Pharma Realizes the Benefits of InstantGMP PRO™ All-In-One Software

Retrieved on: 
Wednesday, November 15, 2023
GMP, Education, SOP, Equipment, Good manufacturing practice, Beauty, Clinical Global Impression, CMOS, MPR, Health, Cosmetics, PRO, BPR, Software, CMO, Communication, Contract manufacturing organization, Good, Fine chemical, Medical device, Warehouse, Asset management, Risk management

CARY, N.C., Nov. 15, 2023 /PRNewswire-PRWeb/ -- InstantGMP™, the industry frontrunner in electronic batch record, quality management, and inventory management software solutions, proudly commemorates two years of support to e2e Pharma, a distinguished Arizona-based Contract Manufacturing Organization (CMO).

Key Points: 
  • A leader in white-label and private-label contract manufacturing across diverse industries, including health, wellness, beauty, cosmetics, and pet products, e2e Pharma continues to benefit immensely from the innovative InstantGMP PRO™ software system.
  • With InstantGMP PRO, e2e Pharma and similar CMOs can improve their manufacturing processes and overall customer experience.
  • Key Benefits of InstantGMP PRO for e2e Pharma and Similar CMOs:
    Streamlined MPR, BPR, and SOP Creation: InstantGMP PRO simplifies the creation of Master Production Records (MPR), Batch Production Records (BPR), and Standard Operating Procedures (SOP).
  • InstantGMP takes immense pride in supporting e2e Pharma's operational excellence by implementing our all-in-one manufacturing, inventory, and quality system.

Berkshire Sterile Manufacturing to Host Webinar on Intravitreal Drug Product Manufacturing

Retrieved on: 
Tuesday, October 31, 2023
Manufacturing, Paratriathlon, CMO, IVT, Contract manufacturing organization, BSM, Pharmaceutical industry, Medical device, Intravitreal administration

Lee, MA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Berkshire Sterile Manufacturing (BSM) will host a webinar focusing on the manufacturing of Intravitreal (IVT) drug products on Wednesday, November 15 at 1PM EST.

Key Points: 
  • Lee, MA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Berkshire Sterile Manufacturing (BSM) will host a webinar focusing on the manufacturing of Intravitreal (IVT) drug products on Wednesday, November 15 at 1PM EST.
  • IVT drug products are vital in treating retinal conditions and can potentially prevent, halt, or even reverse damage that may lead to blindness.
  • During the webinar, participants will gain insight into the unique challenges and requirements involved in the manufacturing of IVT drug products.
  • BSM's webinar is designed to offer practical insights and guidance to pharmaceutical professionals in the field of IVT drug product manufacturing.

WuXi XDC Named Best CDMO Winner at 2023 World ADC Awards

Retrieved on: 
Friday, October 20, 2023
BEST, IND, Investigational New Drug, CDMO, Research, Wuxi, ADC, Spacecraft, Trailblazer, Public, GMP, Patient, Contract manufacturing organization, DNA, Fine chemical, Development

SHANGHAI, Oct. 20, 2023 /PRNewswire/ -- WuXi XDC, a leading global Contract, Resea­­rch, Development, and Manufacturing Organization (CRDMO) focused on the ADC and broader bioconjugate market, announced it has been named the winner of the "Best Contract Development Manufacturing Organization (CDMO)" prize at the 2023 World ADC Awards.

Key Points: 
  • SHANGHAI, Oct. 20, 2023 /PRNewswire/ -- WuXi XDC, a leading global Contract, Resea­­rch, Development, and Manufacturing Organization (CRDMO) focused on the ADC and broader bioconjugate market, announced it has been named the winner of the "Best Contract Development Manufacturing Organization (CDMO)" prize at the 2023 World ADC Awards.
  • Last year, WuXi XDC received the "Best CMO Runner-Up" award.
  • As the most influential award in the global ADC (antibody drug conjugate) field, the World ADC Awards recognize trailblazers that are committed to pioneering innovation, making outstanding contributions to long-term development across the ADC field, and bringing more innovative therapeutic solutions to patients around the world.
  • WuXi XDC emerged the final winner in the "BEST CDMO" category from the nominee short list of six global CDMO companies.

Life Science Outsourcing, Inc. Welcomes Neil A. Goldman as Chief Financial Officer

Retrieved on: 
Tuesday, October 17, 2023
APTV, Senior, Antibody, NYSE, Aptiv, CPH, Acquisition, EBITDA, LSO, Fortune 500, Delphi, US Foods, Electronics, Kidney, Growth, Ernst & Young, Accredited Business Accountant, Contract manufacturing organization, Ernst, Executive, Miami University, Corporate development, CFO, CPA, Pharmaceutical industry, Management, Unwired

BREA, Calif., Oct. 17, 2023 /PRNewswire/ -- Life Science Outsourcing, Inc. ("LSO"), a premier contract manufacturer and value-added service provider for the medical device and life science sectors, announces the appointment of Neil A. Goldman, CPA, as its new Chief Financial Officer ("CFO"), effective October 16, 2023.

Key Points: 
  • BREA, Calif., Oct. 17, 2023 /PRNewswire/ -- Life Science Outsourcing, Inc. ("LSO"), a premier contract manufacturer and value-added service provider for the medical device and life science sectors, announces the appointment of Neil A. Goldman, CPA, as its new Chief Financial Officer ("CFO"), effective October 16, 2023.
  • Mr. Goldman joins LSO from BioPorto A/S (CPH:BIOPOR), a global developer and manufacturer of kidney diagnostics and a portfolio of antibodies.
  • CEO John Nino commented on the appointment, stating, "We are excited to welcome Neil to our executive team.
  • At Unwired, a hi-tech, tier-1 automotive electronics manufacturer, he held positions including Executive Vice President-Corporate Development and CFO, and Senior Vice President-Chief Operating & Financial Officer.

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

Retrieved on: 
Tuesday, October 17, 2023
COGS, WuXi Biologics, ESG, Fed, Contract manufacturing organization, Carbon, Contract research organization, Biopharmaceutical, G&L Musical Instruments, A-DNA, Hook effect, CHO, Bioprocess, Patient, Fine chemical

WuXiUI™ ultra-intensified fed-batch platform offers a new process option for maximum flexibility to meet various clients' needs in biologics development and manufacture.

Key Points: 
  • WuXiUI™ ultra-intensified fed-batch platform offers a new process option for maximum flexibility to meet various clients' needs in biologics development and manufacture.
  • To meet increasing demands for yield improvement, COGS reduction, and ESG consideration in the current bioprocess development, WuXi Biologics has developed WuXiUI™, offering flexible and cost-effective bioprocessing solutions for global clients.
  • WuXiUI™ reduces drug substance manufacturing COGS by an estimated 60-80% compared to traditional fed-batch processes in single-use bioreactors, enhancing the competitiveness of commercial products.
  • Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are pleased to launch the WuXiUI™ platform to provide diverse bioprocessing solutions for global clients that enhance productivity and product quality, and tremendously reduce product COGs.

EQS-News: Abivax provides business and operational update

Retrieved on: 
Saturday, September 16, 2023
Front-end Robotics Enabling Near-term Demonstration, IBD, Bank statement, CMO, IP, Euronext Paris, Investigational New Drug, Patient, Patent, Contract manufacturing organization, CEST, Inflammatory bowel disease, Hand, Combination, PTE, Greater Boston, Safety, Security (finance), Pharmaceutical industry, Medical imaging, EU, Abivax, UC

Inflammatory Bowel Disease (“IBD”) Market

Key Points: 
  • Inflammatory Bowel Disease (“IBD”) Market
    PARIS, France, September 7, 2023 – 08:00 a.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”) today announced updated business and operational goals along with changes to Abivax’s overall strategy, focused on preparing Abivax for the potential commercialization of its investigational lead asset, obefazimod, in IBD.
  • Obefazimod in Crohn’s Disease—Based on existing supportive data, Abivax plans to advance obefazimod in moderately to severely active CD.
  • June Lee and Troy Ignelzi have joined the Abivax Board of Directors to add to existing skills and U.S. competencies and diversity.
  • To help ensure long-term financing and extend its current cash runway, Abivax is implementing a multi-pronged financing strategy.

WuXi Biologics to Increase Manufacturing Capacity in Germany

Retrieved on: 
Thursday, June 1, 2023
WuXi Biologics, Contract research organization, Contract manufacturing organization, Patient, Fine chemical

LEVERKUSEN and WUPPERTAL, Germany, June 1, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it will increase manufacturing capacity in Germany.

Key Points: 
  • -  In response to global clients' increasing demand for contract manufacturing services, WuXi Biologics is expanding its capacity for drug substance and drug product in Germany
    -  As part of WuXi Biologics' global manufacturing network, a new drug product fill line is being installed at its Leverkusen site and the total biomanufacturing capacity is expected to double at its Wuppertal site
    LEVERKUSEN and WUPPERTAL, Germany, June 1, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it will increase manufacturing capacity in Germany.
  • Since 2020, WuXi Bio has significantly invested in the purchase, construction and adaptations of two state-of-the-art manufacturing facilities in Germany, enabling the company to offer end-to-end services spanning the entire biologics manufacturing process.
  • Dr. Benjamin Minow, Managing Director of WuXi Biologics Germany GmbH, added, "WuXi Biologics' increased capacity in Germany is intended to meet the growing needs of our global customers, especially those in Europe, thereby aligning us with the company's global strategy to work in close proximity to our clients.
  • The expansion of the two facilities is a clear commitment to Germany and Europe as high-tech locations and WuXi Biologics' long-term growth strategy."

WuXi Biologics to Increase Manufacturing Capacity in Germany

Retrieved on: 
Thursday, June 1, 2023
WuXi Biologics, Contract research organization, Contract manufacturing organization, Patient, Fine chemical

LEVERKUSEN and WUPPERTAL, Germany, June 1, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it will increase manufacturing capacity in Germany.

Key Points: 
  • -  In response to global clients' increasing demand for contract manufacturing services, WuXi Biologics is expanding its capacity for drug substance and drug product in Germany
    -  As part of WuXi Biologics' global manufacturing network, a new drug product fill line is being installed at its Leverkusen site and the total biomanufacturing capacity is expected to double at its Wuppertal site
    LEVERKUSEN and WUPPERTAL, Germany, June 1, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it will increase manufacturing capacity in Germany.
  • Since 2020, WuXi Bio has significantly invested in the purchase, construction and adaptations of two state-of-the-art manufacturing facilities in Germany, enabling the company to offer end-to-end services spanning the entire biologics manufacturing process.
  • Dr. Benjamin Minow, Managing Director of WuXi Biologics Germany GmbH, added, "WuXi Biologics' increased capacity in Germany is intended to meet the growing needs of our global customers, especially those in Europe, thereby aligning us with the company's global strategy to work in close proximity to our clients.
  • The expansion of the two facilities is a clear commitment to Germany and Europe as high-tech locations and WuXi Biologics' long-term growth strategy."

WuXi Biologics Receives 2023 ISPE Facility of the Year Award for Operations

Retrieved on: 
Monday, May 22, 2023
GMP, Operation, Loo of the Year Awards, Contract manufacturing organization, ISPE, Perfusion, Medication, Recycling, Social Security Government Pension Offset, HPRA, Contract research organization, Patient, Biophysical environment, WuXi Biologics, ESG, Social, International Society, HK, Fine chemical

HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that the International Society for Pharmaceutical Engineering (ISPE) has awarded the company a 2023 Facility of the Year Award (FOYA) in the Operations category.

Key Points: 
  • HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that the International Society for Pharmaceutical Engineering (ISPE) has awarded the company a 2023 Facility of the Year Award (FOYA) in the Operations category.
  • WuXi Biologics was recognized for using innovative solutions while complying with regulatory requirements, overcoming unknown barriers, and upholding project success and product safety in its manufacturing facility in Dundalk, Ireland.
  • Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are very proud to be recognized by ISPE for the second time.
  • In 2014, WuXi Biologics was awarded the FOYA Honorable Mention for its manufacturing facility in Wuxi city, China.